Trials / Completed
CompletedNCT00416962
Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine
An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to assess the safety and pharmacokinetic effects of oseltamivir administration alone or in combination with amantadine in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | amantadine hydrochloride | |
| DRUG | oseltamivir phosphate |
Timeline
- Start date
- 2006-08-01
- Completion
- 2006-12-01
- First posted
- 2006-12-28
- Last updated
- 2007-11-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00416962. Inclusion in this directory is not an endorsement.